Clinical Trials

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT06500273 2026-03-18

ALPHA3

250 enrolled

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT05690984 2026-03-16

EMAT

30 enrolled

Multiple Myeloma, Neoplasm, Residual

NCT03876769 2026-03-13

CASSIOPEIA

121 enrolled

Burkitt Lymphoma, Neoplasm, Residual

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

204 enrolled

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

70 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

119 enrolled

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT04521231 2026-03-06

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

281 enrolled

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07454486 2026-03-06

TRACE-BTC

300 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms, Cholangiocarcinoma, Klatskin Tumor, Neoplasm, Residual

NCT05708235 2026-03-05

MiRaDoR

976 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

46 enrolled

Pathologic Complete Response, Neoplasm, Residual

NCT07069595 2026-03-05

PREDICT-RD

78 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07211178 2026-03-04

GEMINI Breast

900 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07291921 2026-03-03

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

100 enrolled

Lung Neoplasms, Neoplasm, Residual

NCT03516279 2026-03-02

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

40 enrolled

Phase NA Not yet recruiting

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT07443592 2026-03-02

LAL-2025

330 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07136077 2026-02-27

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT07441291 2026-02-27

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Phase 3 Recruiting

70 enrolled

Phase NA Not yet recruiting

Neoplasm, Residual

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

100 enrolled

Colonic Neoplasms, Neoplasm, Residual

NCT05987696 2026-02-11

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Phase 1 Completed

2 enrolled

Phase 2 Not yet recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07392970 2026-02-06

Motixafortide for MRD Sensitization in AML

10 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

31 enrolled

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT05429320 2026-02-02

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

37 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT07382505 2026-02-02

Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer

600 enrolled

Gynecologic

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Neoplasm, Residual

NCT07134088 2026-01-29

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

104 enrolled

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT06693830 2026-01-23

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Phase NA Recruiting

40 enrolled

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT02389517 2026-01-22

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Phase 2 Completed

42 enrolled 11 charts

Multiple Myeloma, Neoplasm, Residual

NCT01499394 2026-01-21

Caris Biorepository Research Protocol

100,000 enrolled

Neoplasms, Neoplasm, Residual

NCT07356882 2026-01-21

EURHOLY

400 enrolled

Neoplasm, Residual

NCT06358430 2026-01-15

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Phase 1 Recruiting

42 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT07025785 2026-01-15

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Phase NA Recruiting

100 enrolled

Breast Neoplasms, Lymphatic Metastasis, Neoplasm, Residual

NCT07112612 2026-01-12

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

50 enrolled

Genitourinary

Prostatic Neoplasms, Neoplasm, Residual

NCT05625971 2026-01-07

NIRVANA

Completed

36 enrolled

Neoplasm, Residual, Neoplasms, Plasma Cell

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

40 enrolled

Phase NA Active not recruiting

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT06744075 2025-12-30

CELERITY

108 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Neoplasm, Residual

NCT05929222 2025-12-24

FIL_GAZEBO

Phase 3 Recruiting

190 enrolled

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, Follicular, Neoplasm, Residual

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

23 enrolled

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04679285 2025-12-23

FERTILAM

Completed

9 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07280494 2025-12-12

S101MRD

Phase 1 Recruiting

18 enrolled

Lymphoma, Neoplasm, Residual

NCT05595408 2025-12-09

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

84 enrolled

Phase 1/2 Not yet recruiting

Neoplasm, Residual

NCT07247201 2025-12-09

AlloNK1

31 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm, Residual

NCT07269067 2025-12-08

DUALFLOW

60 enrolled

Phase 2/3 Not yet recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06730412 2025-12-04

Clear-HPVca

Completed

103 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasm, Residual

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

87 enrolled

Phase 2 Not yet recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07257380 2025-12-02

MRD-ATLAS

90 enrolled

Neoplasm, Residual

NCT07178847 2025-12-01

NeckTAR-IN

Phase NA Recruiting

59 enrolled

Neoplasm, Residual

NCT06663787 2025-11-28

HER2 CR

Active not recruiting

50 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT02666898 2025-11-26

ICLL07GAI

Phase 2 Completed

135 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT04707300 2025-11-20

HTLP-ONCO

10 enrolled